Literature DB >> 10731103

Breast tumor aromatase: functional role and transcriptional regulation.

S Chen1, D Zhou, T Okubo, Y C Kao, C Yang.   

Abstract

Aromatase has been shown to be expressed at a higher level in human breast cancer tissue than in normal breast tissue, by means of enzyme activity measurement, immunocytochemistry, and RT-PCR analysis. Cell culture including MCF-7 breast cancer cells, animal experiments using aromatase-transfected breast cancer cells, and transgenic mouse studies have demonstrated that estrogen production in situ plays a more important role than circulating estrogens in breast tumor promotion. In addition, tumor aromatase is believed to be able to stimulate breast cancer growth through both autocrine and paracrine pathways, as demonstrated by a three-dimensional cell culture study. RT-PCR and gene transcriptional studies have revealed that the aromatase promoter is switched from a glucocorticoid-stimulated promoter, I.4, in normal tissue to cAMP-stimulated promoters, I.3 and II, in cancerous tissue. Recently, we identified and characterized a cAMP-responsive element (CREaro) upstream from promoter I.3 by DNA deletion and mutational analyses. Our results from promoter functional analysis also demonstrated an interaction between the CREaro and the silencer element (S1) that was identified previously in our laboratory. In the presence of cAMP, the positive regulatory CREaro can overcome the action of the silencer on the function of promoter I.3. On the basis of results generated from our own and other laboratories, we propose that, in normal breast adipose stromal cells and fibroblasts, aromatase expression is driven by promoter I.4 (glucocorticoid dependent), and that the action of promoters I.3 and II is suppressed by the silencer negative regulatory element. However, in cancer cells and surrounding adipose stromal cells, the cAMP level increases, and aromatase promoters are switched to cAMP-dependent promoters - I.3 and II. Furthermore, we applied the yeast one-hybrid screening method to search for proteins interacting with the silencer element, S1. The major protein identified was ERRalpha-1; however, SF-1, which is present in the ovary, is not detected in breast cancer tissue. Using a reporter plasmid with the aromatase genomic fragment containing promoter I.3 and S1, in breast cancer SK-BR-3 cells, ERRalpha-1 was found to have a positive regulatory function. It is believed that the silencer element in the human aromatase gene may function differently in different tissues, as a result of distinct expression patterns of transcription factors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10731103     DOI: 10.1677/erc.0.0060149

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  17 in total

Review 1.  Clinical pharmacokinetics of aromatase inhibitors and inactivators.

Authors:  Per Lønning
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells.

Authors:  Hei Jason Chan; Karineh Petrossian; Shiuan Chen
Journal:  J Steroid Biochem Mol Biol       Date:  2015-08-13       Impact factor: 4.292

3.  Modulation of breast cancer risk by nonsteroidal anti-inflammatory drugs.

Authors:  Louise R Howe; Scott M Lippman
Journal:  J Natl Cancer Inst       Date:  2008-10-07       Impact factor: 13.506

4.  Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1.

Authors:  Yin Li; Lutz Birnbaumer; Christina T Teng
Journal:  Mol Endocrinol       Date:  2010-03-08

Review 5.  Aromatase inhibitors and inactivators for breast cancer therapy.

Authors:  Per E Lønning
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

6.  Genetic deletion of microsomal prostaglandin E synthase-1 suppresses mouse mammary tumor growth and angiogenesis.

Authors:  Louise R Howe; Kotha Subbaramaiah; Claire V Kent; Xi K Zhou; Sung-Hee Chang; Timothy Hla; Per-Johan Jakobsson; Clifford A Hudis; Andrew J Dannenberg
Journal:  Prostaglandins Other Lipid Mediat       Date:  2013-04-25       Impact factor: 3.072

7.  Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid.

Authors:  Powel H Brown; Kotha Subbaramaiah; Amoi P Salmon; Rebecca Baker; Robert A Newman; Peiying Yang; Xi Kathy Zhou; Reid P Bissonnette; Andrew J Dannenberg; Louise R Howe
Journal:  Cancer Prev Res (Phila)       Date:  2008-08

8.  Antinociception produced by 14,15-epoxyeicosatrienoic acid is mediated by the activation of beta-endorphin and met-enkephalin in the rat ventrolateral periaqueductal gray.

Authors:  Maia Terashvili; Leon F Tseng; Hsiang-En Wu; Jayashree Narayanan; Lucas M Hart; John R Falck; Phillip F Pratt; David R Harder
Journal:  J Pharmacol Exp Ther       Date:  2008-05-20       Impact factor: 4.030

9.  Alternative use of multiple exons 1 of aromatase gene in cancerous and normal breast tissues from women over the age of 80 years.

Authors:  Naoko Honma; Kaiyo Takubo; Motoji Sawabe; Tomio Arai; Futoshi Akiyama; Goi Sakamoto; Toshiaki Utsumi; Noriko Yoshimura; Nobuhiro Harada
Journal:  Breast Cancer Res       Date:  2009-07-10       Impact factor: 6.466

10.  Tumor aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatment.

Authors:  Marc A Bollet; Alexia Savignoni; Leanne De Koning; Carine Tran-Perennou; Catherine Barbaroux; Armelle Degeorges; Brigitte Sigal-Zafrani; Geneviève Almouzni; Paul Cottu; Rémy Salmon; Nicolas Servant; Alain Fourquet; Patricia de Cremoux
Journal:  Breast Cancer Res       Date:  2009-07-28       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.